191 results
Page 5 of 10
8-K
rua0qg
1 Feb 22
Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board
6:45am
8-K
EX-99.1
mmq01fe 6ztdjo7o1
11 Jan 22
Regulation FD Disclosure
12:00am
8-K
r16 zmf1mn
15 Dec 21
Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors
7:00am
8-K
EX-3.2
06n8bby
8 Nov 21
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s
7:32am
8-K
EX-2.1
663bvux
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
424B5
c7s3v7355 qhp0yiz
11 Aug 21
Prospectus supplement for primary offering
6:56am
8-K
EX-10.1
pq1nfexeas 73i
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-4.1
wo3ih218sv4
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-10.2
hrytzzjm8b
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-4.2
qfn7 thln8lrlzd
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
emg9e82
25 Jun 21
Submission of Matters to a Vote of Security Holders
4:31pm
424B3
53yi vaib135h1i8hdkj
30 Apr 21
Prospectus supplement
5:01pm
DEFA14A
t7v4iczzd
30 Apr 21
Additional proxy soliciting materials
4:07pm
8-K
it1odlhmzk
1 Apr 21
EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors
6:55am